The FDA has approved a new indication for Invokana (canagliflozin; Janssen) to reduce the risk of end-stage renal disease, doubling of serum creatinine, cardiovascular (CV) death, and hospitalization for heart failure (HF) in adults with type 2 diabetes (T2D) and diabetic nephropathy with albuminuria >300mg/day.
Full detailed data will be presented at the AHA Scientific Sessions in Philadelphia in November 2019.
Similar risks of recurrent VTE and major bleeding in morbidly obese with rivaroxaban vs warfarin.
Rybelsus is the first glucagon-like peptide-1 (GLP-1) receptor agonist available in a tablet formulation that is approved for once daily use.
The Food and Drug Administration (FDA) has approved Gvoke (glucagon; Xeris Pharmaceuticals) for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 2 years and older.
Beginning January 2, 2020, Novo Nordisk will be providing new pricing options for their insulin products in the US to support patients without insurance.
Results demonstrated inclisiran to have met both primary end points with a favorable safety profile.
Abrupt interruption or discontinuation of Natpara can result in severe hypocalcemia.
Vyleesi (bremelanotide injection; AMAG Pharmaceuticals) is now commercially available through specialty pharmacies, Avella and BioPlus.
Rozlytrek is a kinase inhibitor that selectively targets ROS1 and NTRK fusions.
